Skip to main content
Erschienen in: Radiological Physics and Technology 3/2020

13.06.2020

Evaluation of bone metastasis burden as an imaging biomarker by quantitative single-photon emission computed tomography/computed tomography for assessing prostate cancer with bone metastasis: a phantom and clinical study

verfasst von: Kazuki Motegi, Norikazu Matsutomo, Tomoaki Yamamoto, Mitsuru Koizumi

Erschienen in: Radiological Physics and Technology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Metabolic bone volume (MBV), standardized uptake value (SUV), and total bone uptake (TBU) are new imaging biomarkers for quantitative bone single-photon emission computed tomography/computed tomography. The purpose of this study was to validate the quantitative accuracy and utility of MBV, SUVmean, and TBU for the assessment of bone metastases in prostate cancer. We used a bone-specific phantom with four hot spheres (φ = 13, 17, 22, 28 mm) filled with different Tc-99 m activities to simulate uptake ratios of 3 and 7, corresponding to normal and metastatic values. We calculated the error ratio (%Error) by comparing MBV, SUVmean, and TBU with true values for various parameters, including bone lesion size, uptake ratio, and SUV cut-off level. Differences for MBV, SUVmean, TBU, and bone scan index (BSI) were calculated to verify their utility in assessing bone metastases. Receiver-operating characteristic curve (ROC) analysis was performed to calculate the area under the curve (AUC) for each biomarker. MBV, SUVmean, and TBU were affected by lesion size, uptake ratio, and SUV cut-off level; however, TBU demonstrated the most stable %Error. The TBU %Error was within 15% in spheres 17 mm or larger when the SUV cut-off level was 7, regardless of the uptake ratio. The ROC analyses revealed the AUCs of BSI (0.977) and TBU (0.968). Additionally, TBU was able to assess bone metastasis when BSI provided false-negative results, but TBU also provided false-positive results by degenerative changes. The synergy between TBU and BSI could potentially improve diagnostic accuracy.
Literatur
1.
Zurück zum Zitat Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014;43:1503–13.CrossRef Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014;43:1503–13.CrossRef
3.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer [Internet] Elsevier Ltd 45:228–47. Doi: 10.1016/j.ejca.2008.10.026 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer [Internet] Elsevier Ltd 45:228–47. Doi: 10.1016/j.ejca.2008.10.026
4.
Zurück zum Zitat Armstrong AJ, Anand A, Edenbrandt L, Bondesson E, Bjartell A, Widmark A, et al. Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4:944–51.CrossRef Armstrong AJ, Anand A, Edenbrandt L, Bondesson E, Bjartell A, Widmark A, et al. Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4:944–51.CrossRef
5.
Zurück zum Zitat Nakajima K, Edenbrandt L, Mizokami A. Bone scan index: a new biomarker of bone metastasis in patients with prostate cancer. Int J Urol. 2017;24:668–73.CrossRef Nakajima K, Edenbrandt L, Mizokami A. Bone scan index: a new biomarker of bone metastasis in patients with prostate cancer. Int J Urol. 2017;24:668–73.CrossRef
6.
Zurück zum Zitat Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Figg MED, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. Jounal Clin Oncol. 1999;17:3461–7.CrossRef Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Figg MED, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. Jounal Clin Oncol. 1999;17:3461–7.CrossRef
7.
Zurück zum Zitat Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol. 2008;26:1148–59.CrossRef Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol. 2008;26:1148–59.CrossRef
8.
Zurück zum Zitat Soloway MS, Hardeman SW, Hickey D, Todd B, Soloway S, Raymond J, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61:195–202.CrossRef Soloway MS, Hardeman SW, Hickey D, Todd B, Soloway S, Raymond J, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61:195–202.CrossRef
9.
Zurück zum Zitat Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, et al. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol. 2012;30:519–24.CrossRef Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, et al. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol. 2012;30:519–24.CrossRef
10.
Zurück zum Zitat Sabbatini BP, Larson SM, Kremer A, Zhang Z, Sun M, Yeung H, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. Jounal Clin Oncol. 1999;17:948–57.CrossRef Sabbatini BP, Larson SM, Kremer A, Zhang Z, Sun M, Yeung H, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. Jounal Clin Oncol. 1999;17:948–57.CrossRef
11.
Zurück zum Zitat Rohren EM, Etchebehere EC, Araujo JC, Hobbs BP, Swanston NM, Everding M, et al. Determination of skeletal tumor burden on 18F-fluoride PET/CT. J Nucl Med. 2015;56:1507–12.CrossRef Rohren EM, Etchebehere EC, Araujo JC, Hobbs BP, Swanston NM, Everding M, et al. Determination of skeletal tumor burden on 18F-fluoride PET/CT. J Nucl Med. 2015;56:1507–12.CrossRef
12.
Zurück zum Zitat Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Prognostic factors in patients treated with 223Ra: The role of skeletal tumor burden on baseline 18F-fluoride PET/CT in predicting overall survival. J Nucl Med. 2015;56:1177–84.CrossRef Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Prognostic factors in patients treated with 223Ra: The role of skeletal tumor burden on baseline 18F-fluoride PET/CT in predicting overall survival. J Nucl Med. 2015;56:1177–84.CrossRef
13.
Zurück zum Zitat Bailey DL, Willowson KP. An evidence-based review of quantitative SPECT imaging and potential clinical applications. J Nucl Med. 2013;54:83–9.CrossRef Bailey DL, Willowson KP. An evidence-based review of quantitative SPECT imaging and potential clinical applications. J Nucl Med. 2013;54:83–9.CrossRef
14.
Zurück zum Zitat Umeda T, Koizumi M, Fukai S, Miyaji N, Motegi K, Nakazawa S, et al. (2018) Evaluation of bone metastatic burden by bone SPECT/CT in metastatic prostate cancer patients: defining threshold value for total bone uptake and assessment in radium-223 treated patients. Ann Nucl Med [Internet]. Springer Japan 32:105–13. Doi: 10.1007/s12149-017-1224-x Umeda T, Koizumi M, Fukai S, Miyaji N, Motegi K, Nakazawa S, et al. (2018) Evaluation of bone metastatic burden by bone SPECT/CT in metastatic prostate cancer patients: defining threshold value for total bone uptake and assessment in radium-223 treated patients. Ann Nucl Med [Internet]. Springer Japan 32:105–13. Doi: 10.1007/s12149-017-1224-x
15.
Zurück zum Zitat De Dreuille O, Strijckmans V, Almeida P, Loc’h CBB. Bone equivalent liquid solution to asses accuracy of transmission measurements in SPECT and PET. IEEE Trans Nucl Sci. 1997;44:1186–90. De Dreuille O, Strijckmans V, Almeida P, Loc’h CBB. Bone equivalent liquid solution to asses accuracy of transmission measurements in SPECT and PET. IEEE Trans Nucl Sci. 1997;44:1186–90.
16.
Zurück zum Zitat Iida H, Hori Y, Ishida K, Imabayashi E, Matsuda H, Takahashi M, et al. Three-dimensional brain phantom containing bone and grey matter structures with a realistic head contour. Ann Nucl Med. 2013;27:25–36.CrossRef Iida H, Hori Y, Ishida K, Imabayashi E, Matsuda H, Takahashi M, et al. Three-dimensional brain phantom containing bone and grey matter structures with a realistic head contour. Ann Nucl Med. 2013;27:25–36.CrossRef
17.
Zurück zum Zitat Cachovan M, Vija AH, Hornegger J, Kuwert T. Quantification of 99mTc-DPD concentration in the lumbar spine with SPECT/CT. EJNMMI Res. 2013;3. Cachovan M, Vija AH, Hornegger J, Kuwert T. Quantification of 99mTc-DPD concentration in the lumbar spine with SPECT/CT. EJNMMI Res. 2013;3.
18.
Zurück zum Zitat Vija H. Introduction to xSPECT* Technology: Evolving Multi-modal SPECT to Become Context-based and Quantitative. White Pap. 2013; Vija H. Introduction to xSPECT* Technology: Evolving Multi-modal SPECT to Become Context-based and Quantitative. White Pap. 2013;
19.
Zurück zum Zitat Chowdhury B, Sjostrom L, Alpsten M, Kostanty J, Kvist H, Lofgren R. A multicompartment body composition based on computerized tomography. Int J Obes Relat Metab Disord. 1994;18:219–34.PubMed Chowdhury B, Sjostrom L, Alpsten M, Kostanty J, Kvist H, Lofgren R. A multicompartment body composition based on computerized tomography. Int J Obes Relat Metab Disord. 1994;18:219–34.PubMed
20.
Zurück zum Zitat Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRef Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRef
21.
Zurück zum Zitat Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Casp J Intern Med. 2013;4:627–35. Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Casp J Intern Med. 2013;4:627–35.
22.
Zurück zum Zitat Armstrong LS, Hoffmann SA. Activity concentration measurements using a conjugate gradient (Siemns xSPECT) reconstruction algorithm in SPECT/CT. Nucl Med Commun. 2016;37:1212–7.CrossRef Armstrong LS, Hoffmann SA. Activity concentration measurements using a conjugate gradient (Siemns xSPECT) reconstruction algorithm in SPECT/CT. Nucl Med Commun. 2016;37:1212–7.CrossRef
23.
Zurück zum Zitat Beck M, Sanders JC, Ritt P, Reinfelder J, Kuwert T. Longitudinal analysis of bone metabolism using SPECT/CT and 99mTc-diphosphono-propanedicarboxylic acid: comparison of visual and quantitative analysis. EJNMMI Res. 2016;60:1–9. Beck M, Sanders JC, Ritt P, Reinfelder J, Kuwert T. Longitudinal analysis of bone metabolism using SPECT/CT and 99mTc-diphosphono-propanedicarboxylic acid: comparison of visual and quantitative analysis. EJNMMI Res. 2016;60:1–9.
24.
Zurück zum Zitat Kaneta T, Ogawa M, Daisaki H, Nawata S, Yoshida K, Inoue T. SUV measurement of normal vertebrae using SPECT/CT with Tc-99m methylene diphosphonate. Am J Nucl Med Mol Imaging. 2016;6:262–8.PubMedPubMedCentral Kaneta T, Ogawa M, Daisaki H, Nawata S, Yoshida K, Inoue T. SUV measurement of normal vertebrae using SPECT/CT with Tc-99m methylene diphosphonate. Am J Nucl Med Mol Imaging. 2016;6:262–8.PubMedPubMedCentral
25.
Zurück zum Zitat Ma J, Vija AH. Comparison of multi modal SPECT reconstruction methods using a clinically relevant assessment of the image resolution at various noise levels. 2014 IEEE Nucl Sci Symp Med Imaging Conf NSS/MIC 2014. 2014; Ma J, Vija AH. Comparison of multi modal SPECT reconstruction methods using a clinically relevant assessment of the image resolution at various noise levels. 2014 IEEE Nucl Sci Symp Med Imaging Conf NSS/MIC 2014. 2014;
26.
Zurück zum Zitat Fischer JE, Bachmann LM, Jaeschke R. A readers’ guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med. 2003;29:1043–51.CrossRef Fischer JE, Bachmann LM, Jaeschke R. A readers’ guide to the interpretation of diagnostic test properties: clinical example of sepsis. Intensive Care Med. 2003;29:1043–51.CrossRef
27.
Zurück zum Zitat Sabbah N, Jackson T, Mosci C, Jamali M, Minamimoto R, Quon A, et al. 18F-sodium fluoride PET/CT in oncology: an atlas of SUVs. Clin Nucl Med. 2015;40:e228–e23131.CrossRef Sabbah N, Jackson T, Mosci C, Jamali M, Minamimoto R, Quon A, et al. 18F-sodium fluoride PET/CT in oncology: an atlas of SUVs. Clin Nucl Med. 2015;40:e228–e23131.CrossRef
28.
Zurück zum Zitat Kuji I, Yamane T, Seto A, Yasumizu Y, Shirotake S, Oyama M. Skeletal standardized uptake values obtained by quantitative SPECT / CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer. Eur J Hybrid Imaging. 2017;1:1–16.CrossRef Kuji I, Yamane T, Seto A, Yasumizu Y, Shirotake S, Oyama M. Skeletal standardized uptake values obtained by quantitative SPECT / CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer. Eur J Hybrid Imaging. 2017;1:1–16.CrossRef
Metadaten
Titel
Evaluation of bone metastasis burden as an imaging biomarker by quantitative single-photon emission computed tomography/computed tomography for assessing prostate cancer with bone metastasis: a phantom and clinical study
verfasst von
Kazuki Motegi
Norikazu Matsutomo
Tomoaki Yamamoto
Mitsuru Koizumi
Publikationsdatum
13.06.2020
Verlag
Springer Singapore
Erschienen in
Radiological Physics and Technology / Ausgabe 3/2020
Print ISSN: 1865-0333
Elektronische ISSN: 1865-0341
DOI
https://doi.org/10.1007/s12194-020-00571-6

Weitere Artikel der Ausgabe 3/2020

Radiological Physics and Technology 3/2020 Zur Ausgabe

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

13.04.2024 Klinik aktuell Kongressbericht

Die Teilnehmer eines Forums beim DGIM-Kongress waren sich einig: Fehler in der Medizin sind häufig in ungeeigneten Prozessen und mangelnder Kommunikation begründet. Gespräche mit Patienten und im Team können helfen.

Wie toxische Männlichkeit der Gesundheit von Männern schadet

08.04.2024 Andrologie Nachrichten

Stark, erfolgreich, allzeit belastbar – das sind Erwartungen, die Jungen und Männer von der Gesellschaft spüren. Das kann sie „toxisch“ werden lassen – und letztlich sogar der Gesundheit schaden, mahnt Dr. Dirk Sander von der Deutschen Aidshilfe.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.